Skip to ContentSkip to Navigation
founded in 1614  -  top 100 university
About us Faculty of Science and Engineering Research at the Faculty of Science and Engineering Groningen Research Institute of Pharmacy - GRIP Pharmaceutical Technology and Biopharmacy

Department of Pharmaceutical Technology and Biopharmacy

Welcome to the homepage of the department of Pharmaceutical Technology and Biopharmacy. Use the links on the left to find relevant information.

The PTB department, which is currently led by Prof. Dr. Peter Olinga, is a place where multiple disciplines come together to conduct both fundamental, and applied research. Our group has many collaborations, which range from pharmaceutical companies, to other research groups within the building. Where our group mostly used to focus on pharmaceutical formulations, drug dosage, medicine administration, we have started to expand our horizon by welcoming research lines focussed on live in-vitro work.

Ultimately, we want to conduct research to make the world a better place, and eradicate preventable/curable diseases. Currently, multiple PhD projects are ongoing on the liver. One of these tries to tackle biliary atresia, a disease affecting newborns' narrowed gallbladder ducts, to which the only viable treatment is transplantations. By culturing these tissue slices post operation, we have the ability to maintain the complex cytoarchitecture of the tissue and test potential drugs. Doing this, we hope to find novel ways to increase viability of diseased tissue, and possibly eradicate the poor prognosis that comes along with the disease. Another project targeting the liver is liver cirrhosis, where healthy liver tissue is gradually becoming irreversibly scarred, preventing proper functioning of the liver. By culturing the precision-cut- liver slices, and incubating them with promising activatiors/inhibitiors of the cirrhosis pathway, we aim to both prevent and treat the disease that affects many individuals, but also find novel biomarkers.

Other great endeavors being done is to make the drug administration experience for patients better. Currently there are diseases in which administration of the drug is highly convoluted, for example, cystic fibrosis. For this, patients need to transform a whole room to house the apparatus which administers antibiotics via the lungs. With our efforts, we try to improve the stability, dosage, particle size, and other factors that come into play, to make inhalation medicine more convenient. By improving these drug formulations, patients would only need a small device like the CYCLOPS® (which has been developed and brougth to the market inhouse) to easily and conveniently treat their disease.

In third world countries, and during the Covid-19 pandemic, logistical difficulties become apparent to facilitate vaccines and other injectable medicine. By rethinking the way we administer these drugs, for example by microneedle patches, we can circumvent all of these problems. The microneedle patch is currently being developed to allow for a slow release, and can be applied by anyone.

New research lines to the PTB are cell-culture based. We focus on efforts on an often overlooked aspects: the extracellular-matrix, and mainly the matrix that is present in the brain, since both our interests are highly focussed on neuroscience. We have hypothesized that during ageing, our cells go through difficult changes not solely form inside cues, but also from environmental influences outside. In this deed versus soil approach, we try to assess mechanical alterations to the extracellular matrix, and how these alterations negatively affect our cells. Our main research endeavors: Advanced Glycation Endproducts (interestingly abbreviated as AGEs), microgravity, the Blood-Brain Barrier, and other projects.

Pharmaceutical Technology and Biopharmacy - May 2019
Pharmaceutical Technology and Biopharmacy - May 2025
Last modified:16 November 2026 2.59 p.m.